Table 2.

Identified factors in the qualitative analysis that positively influence regional-level uptake of biosimilar infliximab and etanercept in England, Wales and Scotland

Factors linked to high rate of biosimilar uptake (qualitative analysis)
A price differential between biosimilar and originator product (= potential cost savings) Gain share agreements, aided by good relationships between commissioner and provider in England Leadership on a regional/local level to implement national policy Key opinion leaders in hospitals that gain early experience and motivate other clinicians